Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet 353 , 883–887 (1999). Article CAS Google Scholar ...

The drug is the only candidate to receive FDA breakthrough designation in the condition, and was granted the status based on phase 2 trial data from patients with IgA nephropathy and other kidney ...

Renalys Pharma completes patient enrollment in registrational phase III trial of sparsentan for IgA nephropathy in Japan: Tokyo, Japan Friday, January 31, 2025, 18:00 Hrs [IST] Re ...

Otsuka is hoping to file for approval of its anti-APRIL antibody sibeprenlimab as a treatment for kidney disorder IgA nephropathy (IgAN) after the drug hit the target in a phase 3 trial.

Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 ...

Considering taking supplements to treat iga nephropathy? Below is a list of common natural remedies used to treat or reduce the symptoms of iga nephropathy. Follow the links to read common uses ...

Renalys Pharma, Inc. (Headquarters: Chuo-ku, Tokyo; "Renalys Pharma") announced today that it has completed patient enrollment for its registrational Phase III clinical trial of sparsentan for the ...

IgA nephropathy is widely known as one of the ... the company aims to address the growing problem of "drug loss" by catalyzing access to new treatments for kidney disease patients in Japan and ...

Following this transaction, Peter retains ownership of 106,374 shares in the company. For investors seeking deeper insights, InvestingPro analysis reveals the company currently operates with moderate ...